Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double‐blind randomized controlled trial
Journal of Cosmetic Dermatology · 2023
DOI: 10.1111/jocd.15715 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2023. Verfasst von Nasrin Saki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Molecular Dermatology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Quality of Life, Hyperhidrosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Palmar hyperhidrosis or excessive palmar sweating can reduce one's quality of life as it is associated with significant physical and occupational disabilities. We compared the gel and nanoemulgel of oxybutynin in treating these patients. Materials and Methods This pilot study was performed as a double‐blind controlled randomized clinical trial at Shahid Faghihi Hospital, Shiraz, Iran. In two randomly allocated groups of 15, patients diagnosed with primary palmar hyperhidrosis by an attending dermatologist applied half a fingertip (roughly 0.25 g) of 1% oxybutynin topical gel or 1% oxybutynin nanoemulgel to both palms every 12 h for one month. The Hyperhidrosis Disease Severity Scale (HDSS), Visual Analog Scale (VAS), and Dermatology Life Quality Index (DLQI) were used to assess the patients at the beginning and end of the study. Statistical analysis was performed using SPSS version 25.
Results
The groups were similar in terms of age ( p = 0.800), sex ( p = 0.096), and baseline HDSS, VAS, and DLQI scores. The mean HDSS scores decreased significantly ( p = 0.001) over time in patients receiving the gel (3.00 ± 1.00 vs. 2.33 ± 0.61) or nanoemulgel (2.92 ± 0.82 vs. 2.14 ± 0.53), without a significant difference between the groups. The same was true for the VAS and DLQI scores. Three patients in each group experienced transient, self‐limited anticholinergic side effects ( p = 0.983).
Conclusion
Oxybutynin gel and nanoemulgel offer equal safety and similar efficacy in reducing the disease severity and increasing the quality of life of patients with palmar hyperhidrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Molecular Dermatology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Dermatology, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Dermatology, Afzalipour Faculty of Medicine, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran.
- Department of Quality Control, Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
- Pathology and Stem cell Research Center, Kerman University of Medical Sciences, Kerman, Iran.
ORCID-Profile: Seyed Ali Hosseini, Najmeh Ahramiyanpour
Zitieren
APA
Saki, N., Shakouri, N., Rastaghi, F., Hosseini, S. A., Alipour, S., & Ahramiyanpour, N. (2023). Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double‐blind randomized controlled trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.15715
Vancouver
Saki N, Shakouri N, Rastaghi F, Hosseini SA, Alipour S, Ahramiyanpour N. Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double‐blind randomized controlled trial. Journal of Cosmetic Dermatology. 2023. doi:10.1111/jocd.15715
BibTeX
@article{Saki2023,
author = {Saki, Nasrin and Shakouri, Negin and Rastaghi, Fatemeh and Hosseini, Seyed Ali and Alipour, Shohreh and Ahramiyanpour, Najmeh},
title = {Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double‐blind randomized controlled trial},
journal = {Journal of Cosmetic Dermatology},
year = {2023},
doi = {10.1111/jocd.15715}
}
EUVIMED